Anna K. Bytzek

Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies

Orsolya Dömötör, Christian G. Hartinger, Anna K. Bytzek et al. · JBIC Journal of Biological Inorganic Chemistry · 2012 · 139 citations

Anticancer Ruthenium, Medicinal Chemistry, Biochemistry +11

Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes

Michael R. Reithofer, Anna K. Bytzek, Seied M. Valiahdi et al. · Journal of Inorganic Biochemistry · 2010 · 122 citations

Medicinal Chemistry, Structural Variation, Biochemistry +11

Physicochemical Studies and Anticancer Potency of Ruthenium η⁶-<i>p</i>-Cymene Complexes Containing Antibacterial Quinolones

Jakob Kljun, Anna K. Bytzek, Wolfgang Kandioller et al. · Organometallics · 2011 · 113 citations · Full text

Anticancer Potency, Medicinal Chemistry, Organometallic Compounds +14

Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action

Anna K. Bytzek, Gunda Koellensperger, Bernhard K. Keppler et al. · Journal of Inorganic Biochemistry · 2016 · 109 citations · Full text

Medicinal Chemistry, Biochemistry, Oncogenic Agent +8

From hydrolytically labile to hydrolytically stable RuII–arene anticancer complexes with carbohydrate-derived co-ligands

Muhammad Hanif, Samuel M. Meier, Wolfgang Kandioller et al. · Journal of Inorganic Biochemistry · 2010 · 65 citations · Full text

Inorganic Chemistry, Medicinal Chemistry, Biochemistry +6